文献速递前列腺癌

PRECISION活检策略在当代MRI靶向活检队列中的应用:多少临床显著前列腺癌被漏诊?

Application of the PRECISION Trial Biopsy Strategy to a Contemporary Magnetic Resonance Imaging-Targeted Biopsy Cohort-How Many Clinically Significant Prostate Cancers are Missed?
PubMed 文献 · J Urol · 2020-10-07

本研究将PRECISION活检策略应用于629例符合纳入标准的男性队列,评估其可推广性及漏诊的临床显著前列腺癌特征。结果显示该策略避免28%的活检,临床显著前列腺癌检出率降低19%,漏诊的临床显著前列腺癌多为小体积、低风险、Gleason分级分组2,且多位于MRI靶向同侧。

要点

  • PRECISION策略在当代队列中避免28%活检,临床显著前列腺癌检出率降低19%。
  • 漏诊的临床显著前列腺癌多小于6 mm、Gleason分级分组2、列线图低风险。
  • 漏诊的临床显著前列腺癌81%位于MRI靶向同侧,可能反映靶向误差。

核心结论

  • 研究队列证实PRECISION发现具有可推广性。
  • 应用PRECISION活检策略大幅降低Gleason分级分组1检出率,但漏诊少量临床显著前列腺癌,通常小体积、低风险、Gleason分级分组2。
  • 漏诊的临床显著前列腺癌主要位于MRI靶向同侧,可能代表靶向误差。

研究设计与样本

  • 回顾性队列研究,纳入629例2015年2月至2018年9月间活检且符合PRECISION纳入标准的男性。
  • PI-RADS 1-2男性仅在临床高度怀疑癌症时活检。
  • 漏诊癌症定义为PI-RADS 3-5男性中仅系统活检发现的前列腺癌,或PI-RADS 1-2男性中系统活检或MRI靶向前列腺活检发现的前列腺癌。

主要发现

  • 应用PRECISION策略避免28%的活检,MRI靶向前列腺活检检出率与PRECISION相似。
  • Gleason分级分组1检出率降低60%,临床显著前列腺癌检出率降低19%。
  • 漏诊的临床显著前列腺癌中54.5%小于6 mm,67.3%为Gleason分级分组2,74.6%经临床列线图评估为低风险。
  • 仅系统活检发现的Gleason分级分组1癌症中46.4%位于MRI靶向对侧,而漏诊的临床显著前列腺癌81%位于同侧。

关键数值与推荐

  • 临床显著前列腺癌定义为Gleason分级分组2或以上。
  • PI-RADS 1-2男性仅在高临床怀疑癌症时活检。
  • 漏诊癌症定义如design所述。

临床怎么用

  • PRECISION策略可安全用于减少不必要活检和低级别前列腺癌检出。
  • 对于PI-RADS 3-5男性,仅靶向活检可能漏诊少量同侧小体积低风险临床显著前列腺癌,需关注靶向误差。
  • PI-RADS 1-2男性应结合临床怀疑决定是否活检。

局限性

  • 仅对PI-RADS 1-2且具有高风险临床特征的男性进行活检,可能高估临床显著前列腺癌检出率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To demonstrate the generalizability of PRECISION findings and apply the PRECISION biopsy strategy to a contemporary cohort to characterize cancers missed by employing this strategy. MATERIALS AND METHODS: A total of 629 men biopsied between February 2015 and September 2018 met PRECISION inclusion criteria. Men with PI-RADS™ 1-2 magnetic resonance imaging were only biopsied if high clinical suspicion for cancer. Missed cancers were defined as prostate cancer identified uniquely on systematic biopsy in men with PI-RADS 3-5 magnetic resonance imaging, or on either systematic biopsy or magnetic resonance imaging-targeted prostate biopsy in men with PI-RADS 1-2 magnetic resonance imaging. Outcomes included 1) clinically significant prostate cancer, Gleason grade group 2 or greater, detection rate, 2) missed clinically significant prostate cancer rate upon application of PRECISION biopsy strategy, 3) Gleason grade group distribution, core size, spatial orientation and oncologic risk among missed cancers. RESULTS: Application of the PRECISION biopsy strategy to the study cohort resulted in avoidance of biopsy in 28%, similar magnetic resonance imaging-targeted prostate biopsy detection rate to PRECISION, reduction of Gleason grade group 1 detection rate by 60% and reduction of clinically significant prostate cancer detection rate by 19%. Missed clinically significant prostate cancers were often smaller than 6 mm (54.5%), Gleason grade group 2 (67.3%) and low risk by clinical nomogram (74.6%). Gleason grade group 1 cancers identified uniquely on systematic biopsy were often contralateral to magnetic resonance imaging target (46.4%), while missed clinically significant prostate cancer was predominantly ipsilateral (81%). Limitations include biopsy of only men with high risk clinical features among PI-RADS 1-2 magnetic resonance imaging, potentially overestimating the clinically significant prostate cancer detection rate. CONCLUSIONS: The study cohort demonstrated generalizability of PRECISION findings. Applying the PRECISION biopsy strategy greatly reduces Gleason grade group 1 detection rate, while missing a small number of clinically significant prostate cancer, typically small volume, low risk, and Gleason grade group 2. Missed clinically significant prostate cancer is predominantly ipsilateral to magnetic resonance imaging target, possibly representing targeting error.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Feuer Z, Meng X, Rosenkrantz AB, et al. Application of the PRECISION Trial Biopsy Strategy to a Contemporary Magnetic Resonance Imaging-Targeted Biopsy Cohort-How Many Clinically Significant Prostate Cancers are Missed? J Urol. 2020. PMID: 33026927. doi:10.1097/JU.0000000000001406

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。